Targeted therapies, aspects of pharmaceutical and oncological management

Cancer Forum

Volumn 37, Issue 1, 2013, Pages 70-80

  Brown, Michael P ^a,b,c,d   Burdett, Nikki ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; B RAF KINASE; BEVACIZUMAB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IPILIMUMAB; LAPATINIB; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; REGORAFENIB; SORAFENIB; STAT3 PROTEIN; SUNITINIB; TRAMETINIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEMURAFENIB;

ARTICLE; BINDING SITE; BREAST CANCER; BREAST METASTASIS; CACHEXIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; CYTOTOXICITY; DRUG APPROVAL; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOCAL THERAPY; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PERITONEUM CANCER; PROGRESSION FREE SURVIVAL; SOFT TISSUE SARCOMA; STOMACH ADENOCARCINOMA; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; THYROID MEDULLARY CARCINOMA; UTERINE TUBE CARCINOMA;

EID: 84879370695     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Robert C, Thomas L, Bondarenko I, O'Day S, Jw MD, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 Jun. 30;364(26):2517-26.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 Aug. 19;363(8):711-23.
3. Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 2012 Feb; 9(2):98-109.
4. Myers MB, Wang Y, McKim KL, Parsons BL. Hotspot oncomutations: implications for personalized cancer treatment. Expert Rev Mol Diagn 2012 Jul; 12(6):603-20.
5. Shahbazian D, Sznol J, Kluger HM. Vertical pathway targeting in cancer therapy. Adv Pharmacol 2012;65:1-26.
6. Reichardt P, Blay JY, Boukovinas I, Brodowicz T, Broto JM, Casali PG, et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol 2012 Nov; 23(11):2776-81.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 Mar. 4;144(5):646-74.
8. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010 Jun. 15;18(6):884-901.
9. Tian T, Olson S, Whitacre JM, Harding A. The origins of cancer robustness and evolvability. Integr Biol (Camb) 2011 Jan; 3(1):17-30.
10. Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol 2007;435:297-321.
11. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007 Jun; 26(2):225-39. (Pubitemid 47101660)
12. Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC. The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol 2011 Oct; 7(10):1223-35.
13. Kacevska M, Robertson GR, Clarke SJ, Liddle C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 2008 Feb; 4(2):137-49. (Pubitemid 351308413)
14. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003 Apr; 4(4):224-32. (Pubitemid 36503320)
15. Zhang L, Daly RJ. Targeting the human kinome for cancer therapy: current perspectives. Crit Rev Oncog 2012;17(2):233-46.
16. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, et al. Genetic progression and the waiting time to cancer. PLoS Comput Biol 2007 Nov; 3(11):e225.
17. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012 Mar. 1;72(5):1070-80.
18. Wang J, Wang C, Li X, Kong L, Gao K, Liu RY. The effects of anti-asthma drugs on the phagocytic clearance of apoptotic eosinophils by A549 cells. Respir Med 2009 Nov; 103(11):1693-9.
19. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitorresistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 2012 Dec; 11(12):2704-8.
20. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008 Oct. 23;359(17):1757-65.
21. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 Sep. 3;361(10):947-57.
22. Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 2010 Feb; 7(2):98-107.
23. Bedard PL, Piccart-Gebhart MJ. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 2008 Dec; 8 Suppl 4: S157-S165.
24. Wagner AD, Thomssen C, Haerting J, Unverzagt S. Vascular- endothelialgrowthfactor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev 2012;7:CD008941.
25. De Gramont A., Van CE, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012 Dec; 13(12):1225-33.
26. Custodio A, Mendez M, Provencio M. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 2012 Feb; 38(1):36-53.
27. Kono SA, Heasley LE, Doebele RC, Camidge DR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets 2012 Feb; 12(2):107-23.
28. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008 May 1;68(9):3077-80.
29. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010 Sep. 30;467(7315):596-9.
30. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011 Jun. 30;364(26):2507-16.
31. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012 Nov. 15;491(7424):399-405.
32. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD anderson cancer center initiative. Clin Cancer Res 2012 Nov. 15;18(22):6373-83.
33. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. Are Fc gamma receptor polymorphisms predictive of the response to monoclonal antibodies in cancer? Haematol Oncol 2013; in press.
34. Peters L, Rischin D. Elusive goal of targeting tumor hypoxia for therapeutic gain. J Clin Oncol 2012 May 20;30(15):1741-3.
35. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 Aug. 26;363(9):809-19.
36. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008 Mar. 13;358(11):1160-74.
37. Bergh J. Quo vadis with targeted drugs in the 21st century? J Clin Oncol 2009 Jan 1;27(1):2-5.
38. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006 Sep. 4;95(5):581-6. (Pubitemid 44325897)
39. Ott PA, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J, et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS ONE 2010;5(12):e15588.
40. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012 Jul. 26;487(7408):505-9.
41. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012 Jun; 23(6):1518-25.
42. Wang ZH, Gao QY, Fang JY. Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. Cancer Chemother Pharmacol 2012 Jun; 69(6):1647-55.
43. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012 Mar. 8;366(10):883-92.
44. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010 Oct. 28;467(7319):1109-13.
45. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012 Jul. 26;487(7408):500-4.
46. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009 Apr. 9;458(7239):719-24.
47. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012 Mar; 2(3):227-35.
48. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010 Dec. 16;468(7326):973-7.
49. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011 Jan 18;19(1):11-5.
50. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 2011 Aug. 1;71(15):5067-74.
51. Motzer R, Hutson TE, Reeves J, Hawkins R, Guo J, Nathan P, et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): Results of the COMPARZ trial. Ann Oncol 2012; LBA8.
52. Long GV, Sosman JA, Daud AI, Weber JS, Flaherty KT, Infante JR, et al. Phase II three-arm randomised study of the BRAF inhibitor (BRAFI) dabrafenib alone vs combination with MEK1/2 inhibitor (MEKI) trametinib in pts with BRAF V600 mutation-positive metastatic melanoma (MM). Ann Oncol 2012;23(suppl. 9):LBA27.
53. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 2013 Feb; 14(2):e60-e69.
54. Choueiri TK, Je Y, Sonpavde G, Galsky MD, Kaymakcalan M, Nguyen PL, et al. Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors. J Clin Oncol (Meeting Abstracts) 2013 Feb. 20;31(6 suppl):347.
55. Schutz FA, Je Y, Richards CJ, Choueiri TK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012 Mar. 10;30(8):871-7.
56. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009 Aug; 6(8):465-77.
57. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 Jul. 24;359(4):378-90.
58. George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 2012 Dec; 23(12):3180-7.
59. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011 May 4;103(9):763-73.
60. Gatzemeier U, Von PJ, Vynnychenko I, Zatloukal P, De MF, Eberhardt WE, et al. First-cycle rash and survival in patients with advanced nonsmallcell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011 Jan; 12(1):30-7.
61. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007 Jul. 1;13(13):3913-21. (Pubitemid 47037599)
62. Abdullah SE, Haigentz M, Jr., Piperdi B. Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management. Chemother Res Pract 2012;2012:351210.
63. Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 2012 Aug. 20;30(24):3012-9.
64. Patel NS, Muneer A, Blick C, Arya M, Harris AL. Targeting vascular endothelial growth factor in renal cell carcinoma. Tumour Biol 2009;30(5-6):292-9.
65. Santoni M, Rizzo M, Burattini L, Farfariello V, Berardi R, Santoni G, et al. Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. Recent Pat Antiinfect Drug Discov 2012 Aug; 7(2):104-10.
66. Gevaert O, Xu J, Hoang CD, Leung AN, Xu Y, Quon A, et al. Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data-methods and preliminary results. Radiology 2012 Aug; 264(2):387-96.
67. Nair VS, Gevaert O, Davidzon G, Napel S, Graves EE, Hoang CD, et al. Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res 2012 Aug. 1;72(15):3725-34.
68. Scholz CW, Pinto A, Linkesch W, Linden O, Viardot A, Keller U, et al. (90) Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013 Jan 20;31(3):308-13.
69. Mathew J, Perez EA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol 2011 Nov; 23(6):594-600.
70. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med 2011 Aug. 10;3(95):95ra73.
71. Wang Z, Rao DD, Senzer N, Nemunaitis J. RNA interference and cancer therapy. Pharm Res 2011 Dec; 28(12):2983-95.
72. Adams JM. Therapeutic potential of a peptide targeting BCL-2 cell guardians in cancer. J Clin Invest 2012 Jun. 1;122(6):1965-7.
73. Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol 2011 Dec; 12(13):1249-57.
74. Brown MP, Buckley MF, Rudzki Z, Olver IN. Why we will need to learn new skills to control cancer. Intern Med J 2007 Mar; 37(3):201-4.